

CORRECTION

Open Access



Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy

Hang-Ping Yao¹, Liang Feng^{2,3}, Sreedhar Reddy Suthre³, Ling-Hui Chen^{4,5}, Tian-Hao Weng¹, Chen-Yu Hu¹, Eun Sung Jun^{6,7}, Zhi-Gang Wu⁴, Wei-Lin Wang^{4,5*}, Song Cheol Kim^{7*}, Xiang-Min Tong^{8*} and Ming-Hai Wang^{1,3,4*}

Correction to: J Immunother Cancer 2019 7:75
<https://doi.org/10.1186/s40425-019-0525-0>

Following publication of the original article [1], the author reported two errors in the authors affiliations:

1. Dr. Song Cheol Kim should be affiliated to Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea;

2. Dr. Eun Sung Jun should be affiliated to Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea and to Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea;

Author details

¹State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ²Cancer Biology Research Center, Hangzhou, China. ³Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center School of Pharmacy, Amarillo, TX, USA. ⁴Zhejiang Provincial Key Laboratory for Precision Diagnosis & Treatment of Hepatic & Pancreatic Oncology, Hangzhou, Zhejiang Province, China. ⁵Division of Hepatobiliary & Pancreatic

Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ⁶Department of Convergence Medicine, Asan Institute for Life Sciences, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea. ⁷Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. ⁸Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.

Received: 20 March 2019 Accepted: 20 March 2019
Published online: 02 April 2019

Reference

1. Yao et al. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy. *Journal for ImmunoTherapy of Cancer*. 2019;7:75. <https://doi.org/10.1186/s40425-019-0525-0>.

* Correspondence: wam@zju.edu.cn; drksc@amc.seoul.kr; tongxiangmin@163.com; minghai.wang@ttuhsc.edu

⁴Zhejiang Provincial Key Laboratory for Precision Diagnosis & Treatment of Hepatic & Pancreatic Oncology, Hangzhou, Zhejiang Province, China
⁷Division of Hepato-Biliary and Pancreatic Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
⁸Department of Laboratory Medicine, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China
¹State Key Laboratory for Diagnosis & Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

